[1. Gilbertson D, Peng Y, Bradbury B, Ebben J, Collins A. Hemoglobin level variability: anemia management among variability groups. Am J Nephrol. 2009; 30: 491-498.10.1159/00024356519786739]Search in Google Scholar
[2. McClellan W, Aronoff S, Bolton W, Hood S, Lorber D, Tang K, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004; 20: 1501-1510.10.1185/030079904X276315383200]Search in Google Scholar
[3. Astor B, Muntner P, Levin A, Eustace J, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2002; 162: 1401-1408.10.1001/archinte.162.12.140112076240]Search in Google Scholar
[4. Kohagura K, Tomiyama N, Kinjo K, Takishita S, Iseki K. Prevalence of anemia according to stage of chronic kidney disease in a large screening cohort of Japanese. Clin Exp Nephrol. 2009; 13: 614-620.10.1007/s10157-009-0197-z19526304]Search in Google Scholar
[5. Stauffer E, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS ONE. 2014; 9: pe84943.10.1371/journal.pone.0084943387936024392162]Search in Google Scholar
[6. Eschbach J. The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989; 35: 134-148.10.1038/ki.1989.182651751]Search in Google Scholar
[7. Zadrazil J, Horak P. Pathophysiology of anemia in chronic kidney diseases: A review. biomed Pap Med Fac Univ Olomouc Czech Repub. 2015; 159: 197-202.10.5507/bp.2013.09324401900]Search in Google Scholar
[8. Babitt J, Lin H. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012; 23: 1631-1634.10.1681/ASN.2011111078345845622935483]Search in Google Scholar
[9. Wagner M, Ashby D. Hepcidin-a well-known iron biomarker with prognostic implications in chronic kidney disease. Nephrol Dialysis Transplant. 2013; 28: 2936-2939.10.1093/ndt/gft33024046195]Search in Google Scholar
[10. Atkinson M, Kim J, Roy C, Warady B, White CT , Furth S. Hepcidin and risk for anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD Cohort. Pediatr Nephrol. 2015; 30: 635-643.10.1007/s00467-014-2991-4433620425380788]Search in Google Scholar
[11. Chonchol M, Lippi G, Montagnana M, Muggeo M, Targher G. Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis. Nephrol Dial Transplant. 2008; 23: 2879-2883.10.1093/ndt/gfn10918326562]Search in Google Scholar
[12. Gupta J, Mitra N, Kanetsky P, Devaney J, Wing M, Reilly M, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012; 12: 1938-1946.10.2215/CJN.03500412351374423024164]Search in Google Scholar
[13. Bruck K, Stel V, Gambaro G, Hallan S, Volzke H, Arnloy J, et al. CKD prevalence varies across the European general population. Am J Soc Nephrol. 2015; 27.10.1681/ASN.2015050542492697826701975]Search in Google Scholar
[14. Chiang C, Tanaka T, Inagi R, Fujita T, Nangaku M. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Invest. 2011; 91: 1564-1571.10.1038/labinvest.2011.11421863063]Search in Google Scholar
[15. Al-Khoury S, Afzali B, Shah N, Thomas S, Gusbeth-Tatomir P, Goldsmith D, et al. Diabetes, kidney disease and anaemia: time to tackle a troublesome triad? Int J Clin Pract. 2007; 61: 281-289.]Search in Google Scholar
[16. Ramey G, Deschemin J, Durel B, Canonne-Hergaux F, Nicolas G, Vaulont S. Hepcidin targets ferroportin for degradation in hepatocytes. Haematologica. 2010; 95: 510-504.10.3324/haematol.2009.014399283308219773263]Search in Google Scholar
[17. Tsuchiya K, Nitta K. Hepcidin is a potential regulator of iron status in chronic kidney disease. Therapeuric Apheresis and Dialysis. 2013; 17: 1-8.10.1111/1744-9987.1200123379486]Search in Google Scholar
[18. Troutt J, Butterfield A, Konrad R. Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates. J Clin Lab Analysis. 2013; 27: 504-510.10.1002/jcla.21634680734024218134]Search in Google Scholar
[19. Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest. 2009; 39: 883-890.10.1111/j.1365-2362.2009.02182.x19563467]Search in Google Scholar
[20. Malyszko , Malyszko J, Pawlak K, Mysliwiek M. Hepcidin, iron status and renal function in chronic renal failure, kidney transplantation and hemodialysis. Am. J. Hematol. 2006; 81: 832-837.]Search in Google Scholar
[21. Uehata T, Tomosugi N, Shoji T, Sakaguchi Y, Suzuki A, Kaneko T, et al. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study. Nephrol. Dial. Transplant. 2012; 27: 1076-1083.]Search in Google Scholar
[22. Peters H, Laarakkers C, Swinkels D, Wetzels J. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol. Dial. Transplant. 2010; 25: 848-853.]Search in Google Scholar
[23. Lukaszyk E, Lukaszyk M, Koc-Zorawska E, Tobolczyk J, Bodzenta- Lukaszyk A, Malyszko J. Iron status and inflammation in early stages of chronic kidney disease. Kidney Blood Press Res. 2015; 40: 366-373.10.1159/00036851226160488]Search in Google Scholar
[24. Mercadel L, Metzger M, Haymann J, Thervet E, Boffa J, Flamant M, et al. The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLos One. 2014; 9: e99781.10.1371/journal.pone.0099781407618924978810]Search in Google Scholar
[25. Young B, Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol. 2009; 4: 1384-1387.10.2215/CJN.0219030919556376]Search in Google Scholar
[26. Fehr T, Ammann P, Garzoni D, Korte W, Fierz W, Rickji H, et al. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int. 2004; 66: 1206-1211.10.1111/j.1523-1755.2004.00880.x15327419]Search in Google Scholar
[27. Mercadel L, Metzger M, Casadevall N, Haymann J, Karras A, Boffa J, et al. Timing and determinants of erythropoietin deficiency in chronic kidney disease. Clin J Am Soc Nephrol. 2012; 7: 35-42.10.2215/CJN.04690511326534922096037]Search in Google Scholar
[28. Camaschella C. Iron-deficiency anemia. N. Engl. J. Med. 2015; 372: 1832- 1843.]Search in Google Scholar
[29. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012; 1823: 1434-1443.10.1016/j.bbamcr.2012.01.014404885622306005]Search in Google Scholar
[30. Rao M, Wong C, Kanetsky P, Girndt M, Sternvinkel P, Reilly M, et al. Cytokine gene polymorphism and progression of renal and cardiovascular diseases. Kidney Int. 2007; 72: 549-556.10.1038/sj.ki.500239117579660]Search in Google Scholar
[31. Pecoits-Filho R, Lindholm B, Axelsson J, Stenvinkel P. Update on interleukin-6 and its role in chronic renal failure. Nephrol Dial Transplant. 2003; 18: 1042-1045.10.1093/ndt/gfg11112748331]Search in Google Scholar
[32. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen B, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin INvest. 2004; 113: 1271-1276.10.1172/JCI200420945]Search in Google Scholar
[33. Yang L, Zhang P, Tang F, Wang F, Li E. Correlation between hepcidin level and renal anemia. Genet Mol Res. 2014; 13: 7407-7410.10.4238/2014.September.12.625222239]Search in Google Scholar
[34. Jairam A, Das R, Aggarwal P, Kohli H, Gupta K, Sakhuja V, et al. Iron status, inflammation and hepcidin in ESRD patients: The confounding role of intravenous iron therapy. Indian Journal of Nephrology. 2010; 20: 125-131.10.4103/0971-4065.70840296697721072151]Search in Google Scholar
[35. Gammella E, Diaz V, Recalcati S, Buratti P, Samaja M, Dey S, et al. Erythropoietin's inhibiting impact on hepcidin expression occurs indirectly. Am J Physiol Regul Integr Comp Physiol. 2015; 308: R330-R335.10.1152/ajpregu.00410.2014434775025519735]Search in Google Scholar
[36. Langdon J, Yates S, Femnou L, McCranor B, Cheadle C. Hepcidindependent and hepcidin-independent regulation of erythropoiesis in a mouse model of anemia of chronic inflammation. Am J Hematol. 2014: 470-479.10.1002/ajh.23670420039524415655]Search in Google Scholar
[37. Song S, Iwahashi M, Tomosugi N, Uno K, Yamana J, Yamana S, et al. Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Res Ther. 2013; 15: R141. 10.1186/ar4323397858024286116]Search in Google Scholar